Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses.

Vilgelm A, Richmond A
Oncoimmunology. 2015 4 (8): e1009299

PMID: 26405565 · PMCID: PMC4570092 · DOI:10.1080/2162402X.2015.1009299

We recently demonstrated that dual therapy combining AURKA and MDM2 antagonists is effective against melanoma in preclinical settings. Notably, besides inducing apoptosis, this regimen led to tumor senescence and stimulated the host's antitumor immune defenses. Treatments leveraging both cancer cell-intrinsic and extrinsic antitumor mechanisms can improve melanoma therapeutic outcomes.

MeSH Terms (0)

Connections (3)

This publication is referenced by other Labnodes entities:

Links